UroGen Pharma (URGN) Enterprise Value (2016 - 2025)
UroGen Pharma (URGN) has disclosed Enterprise Value for 10 consecutive years, with -$112.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 35.23% year-over-year to -$112.1 million, compared with a TTM value of -$112.1 million through Dec 2025, up 35.23%, and an annual FY2025 reading of -$112.1 million, up 35.23% over the prior year.
- Enterprise Value was -$112.1 million for Q4 2025 at UroGen Pharma, down from -$91.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$29.5 million in Q3 2022 and bottomed at -$241.1 million in Q2 2024.
- Average Enterprise Value over 5 years is -$104.1 million, with a median of -$97.9 million recorded in 2022.
- The sharpest move saw Enterprise Value skyrocketed 72.62% in 2023, then tumbled 409.67% in 2024.
- Year by year, Enterprise Value stood at -$45.6 million in 2021, then crashed by 119.29% to -$100.0 million in 2022, then rose by 4.14% to -$95.8 million in 2023, then plummeted by 80.61% to -$173.1 million in 2024, then skyrocketed by 35.23% to -$112.1 million in 2025.
- Business Quant data shows Enterprise Value for URGN at -$112.1 million in Q4 2025, -$91.4 million in Q3 2025, and -$157.0 million in Q2 2025.